338 related articles for article (PubMed ID: 33346789)
1. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial.
Thiele EA; Bebin EM; Bhathal H; Jansen FE; Kotulska K; Lawson JA; O'Callaghan FJ; Wong M; Sahebkar F; Checketts D; Knappertz V;
JAMA Neurol; 2021 Mar; 78(3):285-292. PubMed ID: 33346789
[TBL] [Abstract][Full Text] [Related]
2. Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6.
Wu JY; Cock HR; Devinsky O; Joshi C; Miller I; Roberts CM; Sanchez-Carpintero R; Checketts D; Sahebkar F
Epilepsia; 2022 May; 63(5):1189-1199. PubMed ID: 35175622
[TBL] [Abstract][Full Text] [Related]
3. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial.
Miller I; Scheffer IE; Gunning B; Sanchez-Carpintero R; Gil-Nagel A; Perry MS; Saneto RP; Checketts D; Dunayevich E; Knappertz V;
JAMA Neurol; 2020 May; 77(5):613-621. PubMed ID: 32119035
[TBL] [Abstract][Full Text] [Related]
4. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
5. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
Devinsky O; Patel AD; Cross JH; Villanueva V; Wirrell EC; Privitera M; Greenwood SM; Roberts C; Checketts D; VanLandingham KE; Zuberi SM;
N Engl J Med; 2018 May; 378(20):1888-1897. PubMed ID: 29768152
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K;
Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273
[TBL] [Abstract][Full Text] [Related]
7. Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial.
Thiele EA; Bebin EM; Filloux F; Kwan P; Loftus R; Sahebkar F; Sparagana S; Wheless J
Epilepsia; 2022 Feb; 63(2):426-439. PubMed ID: 34957550
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
[TBL] [Abstract][Full Text] [Related]
9. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
Devinsky O; Marsh E; Friedman D; Thiele E; Laux L; Sullivan J; Miller I; Flamini R; Wilfong A; Filloux F; Wong M; Tilton N; Bruno P; Bluvstein J; Hedlund J; Kamens R; Maclean J; Nangia S; Singhal NS; Wilson CA; Patel A; Cilio MR
Lancet Neurol; 2016 Mar; 15(3):270-8. PubMed ID: 26724101
[TBL] [Abstract][Full Text] [Related]
10. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
Devinsky O; Cross JH; Laux L; Marsh E; Miller I; Nabbout R; Scheffer IE; Thiele EA; Wright S;
N Engl J Med; 2017 May; 376(21):2011-2020. PubMed ID: 28538134
[TBL] [Abstract][Full Text] [Related]
11. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.
Hess EJ; Moody KA; Geffrey AL; Pollack SF; Skirvin LA; Bruno PL; Paolini JL; Thiele EA
Epilepsia; 2016 Oct; 57(10):1617-1624. PubMed ID: 27696387
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive Transdermal Cannabidiol for Adults With Focal Epilepsy: A Randomized Clinical Trial.
O'Brien TJ; Berkovic SF; French JA; Messenheimer JA; Sebree TB; Bonn-Miller MO; Gutterman DL;
JAMA Netw Open; 2022 Jul; 5(7):e2220189. PubMed ID: 35802375
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis.
Lattanzi S; Brigo F; Trinka E; Zaccara G; Cagnetti C; Del Giovane C; Silvestrini M
Drugs; 2018 Nov; 78(17):1791-1804. PubMed ID: 30390221
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US.
Sands TT; Rahdari S; Oldham MS; Caminha Nunes E; Tilton N; Cilio MR
CNS Drugs; 2019 Jan; 33(1):47-60. PubMed ID: 30460546
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.
French JA; Lawson JA; Yapici Z; Ikeda H; Polster T; Nabbout R; Curatolo P; de Vries PJ; Dlugos DJ; Berkowitz N; Voi M; Peyrard S; Pelov D; Franz DN
Lancet; 2016 Oct; 388(10056):2153-2163. PubMed ID: 27613521
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial.
Knupp KG; Scheffer IE; Ceulemans B; Sullivan JE; Nickels KC; Lagae L; Guerrini R; Zuberi SM; Nabbout R; Riney K; Shore S; Agarwal A; Lock M; Farfel GM; Galer BS; Gammaitoni AR; Davis R; Gil-Nagel A
JAMA Neurol; 2022 Jun; 79(6):554-564. PubMed ID: 35499850
[TBL] [Abstract][Full Text] [Related]
17. Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
Silvinato A; Floriano I; Bernardo WM
Rev Assoc Med Bras (1992); 2022; 68(10):1345-1357. PubMed ID: 36417631
[TBL] [Abstract][Full Text] [Related]
18. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
[TBL] [Abstract][Full Text] [Related]
19. A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy.
Ben-Menachem E; Gunning B; Arenas Cabrera CM; VanLandingham K; Crockett J; Critchley D; Wray L; Tayo B; Morrison G; Toledo M
CNS Drugs; 2020 Jun; 34(6):661-672. PubMed ID: 32350749
[TBL] [Abstract][Full Text] [Related]
20. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F
CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
